HESKA CORP
10-Q, EX-27, 2000-11-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: HESKA CORP, 10-Q, 2000-11-14
Next: TARRAGON REALTY INVESTORS INC, 10-Q, 2000-11-14



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION FROM THE REGISTRANT'S
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF AND FOR THE NINE
MONTHS ENDED SEPTEMBER 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) INCLUDED IN THE COMPANY'S
REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2000.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<EXCHANGE-RATE>                                      1
<CASH>                                           2,043
<SECURITIES>                                     7,303
<RECEIVABLES>                                    8,776
<ALLOWANCES>                                     (372)
<INVENTORY>                                      9,317
<CURRENT-ASSETS>                                28,247
<PP&E>                                          26,530
<DEPRECIATION>                                (12,698)
<TOTAL-ASSETS>                                  44,538
<CURRENT-LIABILITIES>                           10,378
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       199,397
<OTHER-SE>                                   (168,966)
<TOTAL-LIABILITY-AND-EQUITY>                    44,538
<SALES>                                         38,533
<TOTAL-REVENUES>                                41,314
<CGS>                                           26,338
<TOTAL-COSTS>                                   26,338
<OTHER-EXPENSES>                                31,016
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               (177)
<INCOME-PRETAX>                               (16,362)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (16,362)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (16,362)
<EPS-BASIC>                                     (0.49)
<EPS-DILUTED>                                   (0.49)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission